Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Janice Mehnert, MD
NYU Langone Health
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Angeles Clinic at Cedars Sinai
Los Angeles, California, United States
Inderjit Mehmi, MDRecruiting - Dana Farber Cancer Institute
Boston, Massachusetts, United States
Stephen Hodi, MDRecruiting - Massachusetts General Hospital
Boston, Massachusetts, United States
Ryan Sullivan, MDRecruiting - Nyu Langone Health
New York, New York, United States
Janice Mehnert, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Feb 2023
- Primary completion
- 31 Aug 2026
- Completion
- 29 Feb 2028
- Last update posted
- 5 Jan 2026
- Registered enrollment
- 105
- Registry id
- NCT05428007
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.